AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Average Rating of “Hold” from Analysts

Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) have been assigned an average rating of “Hold” from the five analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $7.75.

A number of brokerages recently weighed in on ABCL. Weiss Ratings reiterated a “sell (d-)” rating on shares of AbCellera Biologics in a research report on Wednesday, January 21st. Wall Street Zen upgraded shares of AbCellera Biologics from a “sell” rating to a “hold” rating in a report on Saturday, February 14th.

Institutional Trading of AbCellera Biologics

A number of large investors have recently made changes to their positions in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in AbCellera Biologics during the 4th quarter worth $26,938,000. Goldman Sachs Group Inc. grew its stake in AbCellera Biologics by 1,636.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 4,344,485 shares of the company’s stock valued at $14,858,000 after acquiring an additional 4,094,268 shares during the period. Bank of America Corp DE increased its holdings in shares of AbCellera Biologics by 977.8% in the third quarter. Bank of America Corp DE now owns 2,418,304 shares of the company’s stock worth $12,164,000 after acquiring an additional 2,193,939 shares in the last quarter. Tudor Investment Corp ET AL increased its holdings in shares of AbCellera Biologics by 146.0% in the fourth quarter. Tudor Investment Corp ET AL now owns 1,796,010 shares of the company’s stock worth $6,142,000 after acquiring an additional 1,065,888 shares in the last quarter. Finally, Two Sigma Investments LP raised its position in shares of AbCellera Biologics by 25.9% during the third quarter. Two Sigma Investments LP now owns 5,175,142 shares of the company’s stock worth $26,031,000 after purchasing an additional 1,064,290 shares during the period. Institutional investors own 61.42% of the company’s stock.

AbCellera Biologics Trading Up 0.6%

NASDAQ:ABCL opened at $3.49 on Friday. AbCellera Biologics has a 1-year low of $1.89 and a 1-year high of $6.51. The business’s 50-day moving average price is $3.65 and its two-hundred day moving average price is $4.16. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -7.12 and a beta of 0.84.

AbCellera Biologics (NASDAQ:ABCL) last issued its earnings results on Tuesday, February 24th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.15. The firm had revenue of $44.85 million for the quarter, compared to analysts’ expectations of $6.31 million. AbCellera Biologics had a negative return on equity of 15.05% and a negative net margin of 198.37%. Sell-side analysts predict that AbCellera Biologics will post -0.59 earnings per share for the current year.

About AbCellera Biologics

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.